# BioDiem

## Therapies for major infectious diseases and related cancers

Australian Life Science Investment Showcase: New York 18.04.2013

Julie Phillips, CEO www. biodiem.com (ASX:BDM)

## BioDiem Agenda





**Company Focus** 



**Current Achievements** 



**Future Investment Opportunity** 

## BioDiem Challenges

## **BioDiem** Challenges



**Increasing resistance** 

To antibiotics – major concern healthcare systems worldwide



#### Hard to treat

Fungal infections, affecting vulnerable patients



#### No vaccines available

For worldwide diseases eg. hep B, C and D




#### **Product pipelines diminish**

Large Pharma focus on innovation, as product pipelines diminish > acquisition opportunities


## BioDiem Company Focus




## BioDiem Business Model



#### BioDiem Business Model



## BioDiem Business Model



## BioDiem Three core development programs

Target		<b>8</b> Core Technology
Influenza vaccines (seasonal and pandemic)	<b>→</b>	LAIV vaccine – licensed in multiple countries
Vaccine development platforms Hepatitis B/D, nasopharyngeal carcinoma, TB	<b>→</b>	SAVINE technology, LAIV viral vector, flavi and hepatitis virus technologies for novel therapeutic vaccines
Infectious disease therapies Fungal disease: difficult to treat Bacterial disease: MRSA Parasites: Schistosomiasis	<b>→</b>	BDM-I antimicrobial compound

## BioDiem Influenza Vaccines



## BioDiem Flu vaccines

#### Live Attenuated Influenza Virus: LAIV

**Advantages** 



#### Needle-free nasal delivery

No trained personnel and blood/sharps precautions unnecessary



#### Broader immune response

Than seen with inactivated influenza vaccines



#### No adjuvant required



#### Extensive clinical and market experience > 100m doses

In Russia efficacy and safety in >500,000 adults/140,000 children



#### High yields

In egg-based or cell-based production (with no reliance on eggs)

## BioDiem Flu vaccines

#### Live Attenuated Influenza Virus: LAIV

Product	Disease Targets	Current Partners	Development Status
LAIV Vector	Influenza – Seasonal & Pandemic	WHO SII (India) BCHT (China) IEM (Russia)	Marketed with license revenues \$A1.3m FY2012 Phase II (cell-based technology) Seeking growth & out-licensing in more markets
(Influenza)	Avian (Bird) Flu	IEM/WHO	Clinical trials completed in Thailand and Russia

## BioDiem Vaccine development platforms



## BioDiem LAIV Vector & SAVINE


#### **Opportunity to target multiple infectious diseases and related cancers**





Disease Targets	Vaccine development	Nasopharyngeal carcinoma (NPC), tuberculosis (TB)
Current Partners	VIVALIS	In-house
Development Status	First stage of development project completed	Seeking partner for more advanced data in animals

#### BioDiem Hepatitis Vaccine (therapeutic)




Rights licensed from the University of Canberra

R&D program underway

#### BioDiem Dengue Fever vaccine (therapeutic)

Rights licensed from the Australian National University



Technology licensed



Vaccine effect demonstration



Publication pending



Extension into other mosquito-borne disease targets

## BioDiem Infectious disease therapies



#### BioDiem BDM-I antimicrobial disease targets

BDM-I currently in development as treatment against

- 'superbugs' such as antibiotic-resistant bacteria incl. TB, and others
- hard-to-treat fungal infections

Product	Disease Targets	Current Partners	Development Status
	Tuberculosis	US government backed research institutions	Entered in vivo testing in 2013
BDM-I (Antimicrobial)	Fungal infections	US government backed research institutions	Entered in vivo testing in 2013
	Parasitic diseases (schistosomiasis, others)	QIMR program	Entered in vivo testing in 2013

## Expanding Global BioDiem Partnerships and Alliances



#### **Global partnering & commercialisation network**

PATH • USAMRIID

BioReliance VIVALIS • • • WHO

**9** National Institutes of Health

Centres for Disease Control

Institute of Experimental Medicine

**9** BCHT

Serum Institute

QLD Institute of Medical Research Australian National University University of Canberra RMIT Griffith University

#### BioDiem Current Achievements


#### BioDiem License & Pipeline Portfolio

#### **Vaccine Development Pipeline**

	Research	Preclinical	Phase I	Phase II	Phase III	Marketed
Influenza vaccines	Cell based production					
(Seasonal	Egg based production					
and Pandemic) Licensed to World Health Organisation for public markets in Developing Countries Licensed to Serum Institute of India and Changchun BCHT Biotech Co. for certain Developing				ntry private markets		
LAIV Viral Vector platform						
Hepatitis D platform (Hepatitis D /Hepatitis B therapeutic vaccine)						
Flavivirus platform (Dengue fever, West Nile, Murray River encephalitis)						
SAVINE antigen technology (Tuberculosis, NPC)						

## BioDiem Pipeline Portfolio

#### **BDMI-I Development Pipeline**



## BioDiem Partnership Portfolio

#### **Expanding Global Partnership Network**



US Army Research Institute of Infectious Diseases (USAMRIID)

Queensland Institute of Medical research (QIMR)

University of Canberra, Australia

AUSTRALIA'S CAPITAL UNIVERSITY

#### BioDiem Future Investment Opportunity



#### BioDiem Market Size Potential

Vaccine market US\$52b by 2016

Anti-infectives market market, US\$103 billion by 2015

Antifungals market, US\$12.2 billion by 2016 Global antibacterials market, US\$46 billion by 2017

## BioDiem BioDiem Limited

As at 31 March 2013		
Market Cap	\$5.12 M	
52 week range	\$0.036 - \$0.09	
Cash as of 31-12-12	\$2,324, 909	
Shares	142,105,934	
Shareholders	919	
Listed Options	24,638, 574	

#### Hugh Morgan



AC - Chairman

#### **Julie Phillips**



CEO

#### **Prof Larisa Rudenko**



Non-executive Director

**Prof Arthur Li** 



Non-executive Director

#### Don Brooks



#### Non-executive Director

## BioDiem Next 12 months



Additional license revenues



Clinical trial results



Vector program



Results from expanded studies



Hepatitis vaccine progress



Expand sales and use of LAIV in new territories



BDM-I testing in animal models



Completion of BDM-E out-licensing or sale

# BioDiem

## Therapies for major infectious diseases and related cancers

Australian Life Science Investment Showcase: New York 18.04.2013

Julie Phillips, CEO www. biodiem.com (ASX:BDM)